There are currently 1572 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
NCT03251118
Recruiting
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
2 years and above
Trial Updated:
10/27/2023
Locations: UT Southwestern, Dallas, Texas
Conditions: Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
Register for Updates
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
NCT05082519
Recruiting
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even those who start chemotherapy at a healthy weight. This study is being done to find out if caloric restriction achieved by a personalized nutritional menu and exercise plan during routine chemotherapy... Read More
Gender:
All
Ages:
Between 10 years and 25 years
Trial Updated:
10/25/2023
Locations: University of Texas, Southwestern, Dallas, Texas
Conditions: B-cell Acute Lymphoblastic Leukemia, Obesity
Register for Updates
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
NCT04997902
Recruiting
This phase 1/2 combination trial of tipifarnib, a farnesyltransferase inhibitor, and alpelisib, a PI3K inhibitor in participants with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) whose tumors overexpress the HRAS protein and/or are PIK3CA-mutated and/or PIK3CA-amplified.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: UT Southwestern Medical Center (Harold C. Simmons Comprehensive Cancer Center), Dallas, Texas
Conditions: HNSCC
Register for Updates
Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
NCT05203939
Recruiting
This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations and in patients with LCA due to mutation(s) in CEP290 gene (OCU400-101). To document prospective eye pathology in the above subjects Investigators will also conduct a Natural History Study (OCU400-104)i This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 24 subjects in the OCU400-101 and 100 subjects i... Read More
Gender:
All
Ages:
6 years and above
Trial Updated:
10/24/2023
Locations: Ocugen Site 1 - Retina Foundation of the Southwest, Dallas, Texas
Conditions: Retinitis Pigmentosa, Leber Congenital Amaurosis
Register for Updates
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646
Recruiting
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an... Read More
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
10/24/2023
Locations: ACTION3 Investigational Site 2, Dallas, Texas +1 locations
Conditions: FSGS
Register for Updates
Brain Metabolism Observed at 7 Tesla
NCT05085704
Recruiting
The goal is to develop methodology to monitor flux in the citric acid cycle in brain via 13C nuclear magnetic resonance (NMR) spectroscopy at 7 Tesla.
Gender:
All
Ages:
Between 16 years and 65 years
Trial Updated:
10/23/2023
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Glut1 Deficiency Syndrome 1, Glucose Metabolism Disorders, Epilepsy, Glut1 Deficiency Syndrome 1, Autosomal Recessive, Glucose Transporter Type 1 Deficiency Syndrome, Glucose Transporter Protein Type 1 Deficiency Syndrome, Glucose Transport Defect
Register for Updates
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
NCT05651932
Recruiting
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
Gender:
All
Ages:
18 years and above
Trial Updated:
10/23/2023
Locations: University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas
Conditions: Multiple Myeloma, Myeloma, Myeloma Multiple
Register for Updates
A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
NCT04554914
Recruiting
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.
Gender:
All
Ages:
All
Trial Updated:
10/23/2023
Locations: University of Texas Southwestern Medical Center (Pediatrics only), Dallas, Texas
Conditions: Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
Register for Updates
A Study of DCR-STAT3 in Adults With Solid Tumors
NCT06098651
Recruiting
This is a sequential, ascending-dose, multicenter study conducted in patients with refractory solid tumors designed to evaluate the safety, tolerability, and pharmacokinetics of DCR-STAT3.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/21/2023
Locations: Next Oncology, Dallas, Texas
Conditions: Solid Tumor, Adult, Refractory Tumor
Register for Updates
A Retrospective Analysis of Outcomes in Patients With Hepatorenal Syndrome at Methodist Dallas Medical Center
NCT06095440
Recruiting
Hepatorenal syndrome (HRS) is a common cause of acute kidney injury (AKI) in patients with liver disease [1]. Increased activity and presence of vasodilators such as nitric oxide in cirrhotic patients leads to vasodilation, especially in the splanchnic circulation, resulting in hemodynamic changes that precipitate renal injury [1]. Patients may present with elevated serum creatinine (Cr), benign urine sediment, and low urine sodium [1].
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
10/18/2023
Locations: Liver Institute of Methodist Dallas Medical Center, Dallas, Texas
Conditions: Hepatorenal Syndrome
Register for Updates
Cerebellar Transcranial Direct Current Stimulation (tDCS) in Children With Autism Spectrum Disorder: Raynor Cerebellum Project
NCT05691283
Recruiting
The purpose of this research study is to investigate the effects of transcranial direct current stimulation (tDCS) on some of the challenges faced by children with Autism Spectrum Disorder (ASD).
Gender:
All
Ages:
Between 5 years and 21 years
Trial Updated:
10/18/2023
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Autism Spectrum Disorder
Register for Updates
Improving Control of Alignment in Intermittent Exotropia
NCT04199871
Recruiting
Aim 1: To determine whether use of dichoptic movies for 4 weeks may be helpful in improving control of alignment in children with intermittent exotropia (IXT), thus allowing IXT to be managed non-surgically Aim 2: To determine pre-IXT surgery use of dichoptic movies for 4 weeks post-operatively may be helpful in maintaining successful control of alignment in children who have surgical correction of IXT
Gender:
All
Ages:
Between 3 years and 12 years
Trial Updated:
10/18/2023
Locations: Eileen E Birch, Dallas, Texas
Conditions: Intermittent Exotropia
Register for Updates